The health and economic repercussions of declining MMR coverage in the United States

Chad R. Wells, Abhishek Pandey, Y. Ye, Carolyn E. Bawden, Rebecca Giglio, Charlene A. Wong, Velda Wang, Chelsea Cipriano, Lamia Ayaz, Gergely Rost, Seyed M Moghadas, Meagan C. Fitzpatrick, Burton H. Singer, Alison P. GalvanimedRxiv 2026 · DOI

Abstract

The resurgence of measles in the United States, driven by declining childhood vaccination coverage, poses a substantial public health and economic threat. Using county-level MMR vaccine coverage data and spatial incidence models, we quantified the economic burden of measles in 2025 and projected the impact of continued declines in vaccine uptake. In 2025, the estimated cost per measles case was $104,629 (50% HDI: $100,729–$110,140), yielding a national burden of $244.2 million (50% HDI: $69.9–$872.5 million). We modeled a scenario in which coverage among children aged 0–6 years declined by 1% per year, reaching a 5% absolute reduction by year 5. Under this scenario, we projected a nonlinear surge in cases and expenditures, totaling $7.77 billion (50% HDI: $5.56–$11.58 billion) over five years. These findings demonstrate that even marginal reductions in MMR vaccine uptake can result in disproportionately large health and economic burdens.

Introduction

In 2000, the United States achieved a landmark public health milestone: the declaration that measles had been eliminated from the country. However, this status is increasingly fragile. Recent years have seen a decline in childhood Measles-Mumps-Rubella (MMR) vaccination coverage, fueled by policy shifts, changes in Medicaid funding, and rising vaccine hesitancy. While the clinical risks of measles—ranging from severe respiratory distress to encephalitis—are well-documented, the broader societal and economic consequences of its resurgence have remained under-explored.

This research addresses this gap by providing a granular, county-level analysis of the economic and health impacts of declining MMR coverage. By linking localized vaccination gaps to outbreak risks, the study quantifies the full spectrum of costs, including public health response efforts, direct medical care, and lost productivity.

Methodology: An Integrated Modeling Framework

To capture the complexity of measles transmission and its associated costs, the researchers developed an integrated modeling framework consisting of four primary components:

  1. Coverage and Immunity Estimation: Using an insurance-stratified logistic regression model, the authors inferred MMR coverage across U.S. counties. This model incorporated socio-demographic factors such as income, education, and local exemption policies. These data were then translated into age-structured immunity profiles, accounting for the two-dose vaccine schedule.
  2. Transmission and Spatial Spread: The model accounted for international importations and domestic spread via a "gravity model," which assumes that connectivity between areas is a function of population size and geographic distance. Within counties, transmission was simulated using an age-structured final-size framework.
  3. Economic Valuation: The model categorized costs into three primary buckets:
  4. Public Health Response: Contact tracing, testing, and emergency vaccination efforts.
  5. Direct Medical Costs: Outpatient visits and hospitalizations.
  6. Productivity Losses: The economic impact of missed work and school for patients and caregivers.
  7. Uncertainty Analysis: The team utilized 2,500 Monte Carlo simulations to generate 50% High-Density Intervals (HDIs), ensuring the robustness of their projections against statistical variance.

The "Invisible" Cost of Outbreaks

One of the study's most striking findings is that the most visible costs of measles—hospitalizations and medical treatments—represent only a tiny fraction of the total economic burden. Direct medical costs account for less than 3% of the total financial impact of an outbreak.

The true burden is largely "invisible" to the general public. Approximately 65% of the costs are absorbed by the public health infrastructure through intensive contact tracing and outbreak containment efforts. Another 32% stems from productivity losses as parents and patients are forced out of work and school. In the 2025 baseline, the national economic burden was estimated at $244.2 million, with an average cost of $104,629 per individual case.

The Nonlinear Threat of Declining Coverage

The research highlights a dangerous nonlinearity in how vaccine coverage affects public health. A seemingly minor 1% annual decline in MMR coverage among children aged 0–6 does not lead to a simple 1% increase in cases. Instead, it triggers a massive surge due to the rapid erosion of herd immunity.

Under a scenario of 1% annual decline, the model projects that by 2030:

  • Annual measles cases would surge to 17,232 (compared to 2,181 in the 2025 baseline).
  • Annual hospitalizations would reach 4,085.
  • Annual economic costs would hit $1.50 billion.
  • Cumulative five-year costs (2026–2030) would reach a staggering $7.77 billion.

Even a more conservative 0.5% annual decline results in significant escalation, with projected annual costs of $630.2 million by 2030. This demonstrates that the relationship between vaccination rates and outbreak scale is not additive, but exponential once certain thresholds are crossed.

Heterogeneity and Local Risk

The cost per case is not uniform across the country. The study found a strong inverse correlation (Spearman correlation = -0.75) between local population immunity and the cost per case. Counties with lower baseline immunity face significantly higher per-case costs because outbreaks in these "pockets of vulnerability" require more aggressive, widespread, and expensive public health interventions to contain.

Conclusion and Limitations

The estimates provided in this study are likely conservative. The model excludes long-term human capital losses from missed schooling and the costs associated with rare but severe long-term complications like subacute sclerosing panencephalitis (SSPE). Furthermore, the analysis did not include the statistical value of lives lost; including this metric would increase the 2030 projections by over $500 million.

The findings underscore a critical reality: the economic and health stability provided by high vaccination rates is easily disrupted. Marginal declines in MMR uptake can lead to disproportionately large financial and human costs, emphasizing the urgent need for policies that support and maintain high levels of community immunity to protect both the public health and the national economy.

Summary updated

Abstract

Abstract The resurgence of measles in the United States, driven by declining childhood vaccination coverage, poses a substantial public health and economic threat. Using county-level MMR vaccine coverage data and spatial incidence models, we quantified the economic burden of measles in 2025 and projected the impact of continued declines in vaccine uptake. In 2025, the estimated cost per measles case was $104,629 (50% High-Density Interval [HDI]: $100,729–$110,140), yielding a national burden of $244.2 million (50% HDI: $69.9–$872.5 million). The cost per case varied widely across counties and was inversely correlated with local population immunity levels (Spearman correlation = -0.75, p < 0.001). We modeled a scenario in which coverage among children aged 0–6 years declined by 1% per year, reaching a 5% absolute reduction by year 5 relative to baseline. Under this scenario, we projected a nonlinear surge in cases, hospitalizations, and annual expenditures arising from outbreak response, direct medical costs, and productivity losses. This scenario produced 17,232 (50% HDI: 9,177–26,428), 4,085 (50% HDI: 2,184–6,210) hospitalizations, 36 (50% HDI: 19–54) deaths, and $1.50 (50% HDI: $0.90–$2.85) billion in annual costs in 2030, with a cumulative cost of $7.77 billion (50% HDI: $5.56–$11.58 billion) over 5 years. These findings demonstrate that even marginal reductions in MMR vaccine uptake can result in disproportionately large health and economic burdens. Significance Statement The United States is experiencing a resurgence of measles amid recent declines in childhood MMR vaccination. Using mathematical modeling informed by spatially resolved data on vaccination coverage, incidence, and associated economic costs, we quantified both the current and projected financial burden of measles in the United States under continued declines in coverage. For 2025, we estimated that measles imposes a cost of $244.2 million nationwide, with substantial heterogeneity in cost per case across counties driven by gaps in population immunity. Even modest annual reductions in vaccine coverage among young children generate a nonlinear increase in cases and hospitalizations, with costs totaling $7.77 billion over a five-year period.
BibTeX
@misc{wells2026health,
  author = {Chad R. Wells and Abhishek Pandey and Y. Ye and Carolyn E. Bawden and Rebecca Giglio and Charlene A. Wong and Velda Wang and Chelsea Cipriano and Lamia Ayaz and Gergely Rost and Seyed M Moghadas and Meagan C. Fitzpatrick and Burton H. Singer and Alison P. Galvani},
  title = {{The health and economic repercussions of declining MMR coverage in the United States}},
  year = {2026},
  doi = {10.64898/2026.02.19.26346619},
  howpublished = {medRxiv},
}
Figure